ClinicalTrials.gg
WithdrawnNCT04666675Updated Apr 8, 2021

A Study of Oral Upadacitinib Tablets to Assess Change in Disease State in Participants Aged 12-75 Years With Moderate to Severe Atopic Dermatitis in Brazil

A Phase 3 interventional study of Upadacitinib and Placebo for Upadacitinib in Atopic Dermatitis (AD), sponsored by AbbVie. Withdrawn. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-04-08.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Strategic considerations

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
12 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing upadacitinib in Dermatitis, Atopic — 2 open to participants now, 6 under way, 4 of them phase 3. upadacitinib · Dermatitis, Atopic.

Enrollment
16th of 17
0 · median 272
Started
2020
with 1 other
Phase 3
12 of 17
none open now
Registered
9th of 17
by date
Lead sponsor
15 of 17
AbbVie

Among the 17 studies testing upadacitinib in Dermatitis, Atopic, this one is the 16th largest by enrollment, is one of 2 that started in 2020, is one of 12 in phase 3, and was the 9th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

2 of the 17 studies testing upadacitinib in Dermatitis, Atopic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About upadacitinib

upadacitinib: first FDA approval 2019 (RINVOQ), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 12 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing upadacitinib in Dermatitis, Atopic, or all of them as a file.
02

Study summary

Atopic Dermatitis (AD) is a chronic inflammatory skin disease that is characterized by intense itching, oozing and crusting, redness, skin erosion and dry skin. This study will evaluate how well upadacitinib compared to placebo (no medicine) works to treat participants with moderate to severe AD in Brazil. The study will assess change in disease signs and symptoms.

Upadacitinib is an investigational drug being developed for the treatment of Atopic Dermatitis (AD). This study is "double-blinded", which means that neither the trial participants nor the study doctors will know who will be given which study drug. Study doctors put the participants into 1 of 4 groups called treatment arms. Each group receives a different treatment. Participants with a diagnosis of AD will be enrolled. Around 150 participants will be enrolled in the study in approximately 20 sites in Brazil.

Participants will receive the following for up to 52 weeks:

Participants will receive oral upadacitinib tablets once daily for up to week 52. Participants may also receive oral placebo tablets once daily up to week 16 followed by oral upadacitinib tablets once daily up to week 52.

Arm 1: Upadacitinib Dose A up to week 52. Arm 2: Upadacitinib Dose B up to week 52. Arm 3: Placebo up to week 16 followed by upadacitinib Dose A up to week 52. Arm 4: Placebo up to week 16 followed by upadacitinib Dose B up to week 52.

There may be higher burden for participants in this trial compared to their standard of care. Participants will attend monthly visits during the course of the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, and checking for side effects.

03

Conditions studied

  • Atopic Dermatitis (AD)

Browse trials for

Keywords

  • Atopic Dermatitis
  • Upadacitinib
  • ABT-494
  • Rinvoq
04

Who can participate

Ages eligible
12 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight >= 40 kg at the Baseline Visit for participants between >= 12 and \< 18 years of age.
  • Chronic Atopic Dermatitis (AD) with onset of symptoms at least 3 years prior to Baseline and participant meets Hanifin and Rajka criteria.
  • Eczema Area and Severity Index (EASI) score >= 16 at the Screening and Baseline Visits.
  • Validated Investigator Global Assessment for AD (vIGA-AD) score ≥ 3 at the Screening and Baseline Visits.
  • >= 10% body surface area of AD involvement at the Screening and Baseline Visits.
  • Worst Pruritus Numerical Rating Scale (NRS) ≥ 4 at Screening and Baseline Visits.
  • Documented history (within 1 year prior to the Screening Visit) of inadequate response (IR) to systemic methotrexate (MTX) and/or cyclosporin A (CsA) or not a candidate for systemic treatment with MTX or CsA as a result of intolerance or medical .

Exclusion criteria

Exclusion Criteria:

  • Prior exposure to any systemic Janus kinase (JAK) inhibitor.
  • Prior exposure to dupilumab.
  • Must not have used the following AD treatments within the specified timeframe prior to Baseline Visit:

    • , MTX, CsA, azathioprine. phosphodiesterase type 4 (PDE4)-inhibitors, interferon-γ, and mycophenolate mofetil within 4 weeks.
    • Targeted biologic treatments (refer to within 5 half-lives [if known]) or within 12 weeks, whichever is longer.
    • Phototherapy treatment, laser therapy, tanning booth, or extended sun exposure that could affect disease severity or interfere with disease assessments within 4 weeks.
    • Oral or parenteral traditional medicine within 4 weeks.
    • Moisturizers that contain Topical corticosteroids (TCS), Topical calcineurin inhibitor (TCI)s, or topical Phosphodiesterase type 4 (PDE-4) inhibitors within 7 days.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Upadacitinib Dose A

    Participants will receive Upadacitinib Dose A once daily (QD).

    Drug: Upadacitinib

  • Experimental
    Upadacitinib Dose B

    Participants will receive Upadacitinib Dose B QD.

    Drug: Upadacitinib

  • Experimental
    Placebo for Upadacitinib Followed by Upadacitinib Dose A

    Participants will receive placebo for Upadacitinib followed by Upadacitinib Dose A QD.

    Drug: Upadacitinib · Drug: Placebo for Upadacitinib

  • Experimental
    Placebo for Upadacitinib Followed by Upadacitinib Dose B

    Participants will receive placebo for Upadacitinib followed by Upadacitinib Dose B QD.

    Drug: Upadacitinib · Drug: Placebo for Upadacitinib

Interventions

  • Oral; Tablet

    Also known as: Rinvoq, ABT-494

  • DrugPlacebo for Upadacitinib

    Oral; Tablet

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving at least a 75% Reduction in Eczema Area and Severity Index (EASI 75) from Baseline

    The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of atopic dermatitis (AD).

    Time frame: Baseline to Week 16

  2. Number of Participants With Adverse Events (AE)

    An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to Week 52

Secondary outcomes

  1. Percentage of Participants Achieving at least a 90% Reduction in Eczema Area and Severity Index (EASI 90) from Baseline

    The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD.

    Time frame: Baseline to Week 16

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · www.abbvie.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2020.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2020
First posted
Dec 14, 2020
StartEst.
Dec 24, 2020
Primary completionActual
Mar 23, 2021
CompletionActual
Mar 23, 2021
Last update
Apr 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04666675
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Dec 14, 2020
Start date
Dec 24, 2020 (estimated)
Primary completion
Mar 23, 2021
Completion
Mar 23, 2021
Last update
Apr 8, 2021

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Upadacitinib

Start the discussion